Regaining compliance with Nasdaq's minimum bid price requirement is a positive development for Virios Therapeutics. This news may boost investor confidence in the stock, as it indicates that the company has met a key listing requirement, reducing the risk of delisting. As a result, the stock price may experience a short-term positive impact.